β-Tubulin-II Expression Strongly Predicts Outcome in Patients Receiving Induction Chemotherapy for Locally Advanced Squamous Carcinoma of the Head and Neck: A Companion Analysis of the TAX 324 Trial
Kevin J. Cullen(University of Maryland, Baltimore), Marshall R. Posner(Icahn School of Medicine at Mount Sinai), Nicholas J. Sarlis(Incyte (United States)), Nikolaos G. Nikitakis(National and Kapodistrian University of Athens), Olga Goloubeva(University of Maryland, Baltimore), Lisa M. Schumaker, Robert I. Haddad(Georgetown University), Ming Tan(University of Maryland, Baltimore)
Cited by 59
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Recent Advances in Head and Neck Cancer
|New England Journal of Medicine|2008|926